Investigating infections after spleen removal in cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients who have undergone splenectomy alongside complete cytoreductive surgery for peritoneal malignancies. It aims to assess the incidence of overwhelming post-splenectomy infections (OPSI) and evaluate patient compliance with prescribed prophylactic antibiotics. Participants will be contacted via telephone to gather data on their experiences and health outcomes following surgery. The study seeks to provide insights into the effectiveness and risks associated with current infection prevention strategies in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged \>18 and \<80 years
* Patients capable of providing informed consent
* Patients who have a splenectomy in conjunction with complete cytoreductive surgery (CRS) for any pathology

Exclusion Criteria:

* Patients who are \<18 and \>80
* Patients who do not provide informed consent
* Patients on immunosuppression therapy

Where it's running

• The Peritoneal Malignancy Institute, Hampshire Hospitals NHS Foundation Trust
  Basingstoke, Hampshire, United Kingdom Recruiting

Study contacts

• Principal investigator: Brendon Moran — Hampshire Hospitals NHS Foundation Trust
• Study coordinator: Victoria Corner
• Email: victoria.corner@hhft.nhs.uk
• Phone: 01962 824127

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Raludotatug Deruxtecan With or Without Bevacizumab as First‑Line Maintenance in Advanced Ovarian Cancer

  This trial tests whether maintenance therapy with raludotatug deruxtecan, with or without bevacizumab, helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer without the cancer growing after initial treatment.

  Recruiting at 13 sites Phase 3 Merck Sharp & Dohme LLC · Washington D.C., District of Columbia and 12 other locations · NCT07776691

• Raludotatug Deruxtecan with or without Bevacizumab for advanced ovarian, peritoneal, or fallopian tube cancer

  This trial tests whether adding raludotatug deruxtecan (R-DXd) to or without bevacizumab helps people with advanced ovarian cancer that progressed after PARP-inhibitor maintenance.

  Recruiting at 7 sites Phase 3 Merck Sharp & Dohme LLC · Fountain Valley, California and 6 other locations · NCT07743164

• Personalized timing of interval debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.

  This study will see if using the CA125 drop rate (KELIM) to decide when to do interval debulking surgery helps people with advanced ovarian, fallopian tube, or peritoneal cancer who are receiving neoadjuvant chemotherapy.

  Recruiting Phase 2 The University of Hong Kong · Hong Kong · NCT07022535

• Direct injection of a modified vaccinia virus (vvDD-hIL2) into abdominal and gastrointestinal tumors

  This trial will try a single direct injection of a modified vaccinia virus (vvDD-hIL2) into abdominal tumors to see if it is safe for adults with advanced metastatic gastrointestinal or peritoneal cancers who have not responded to standard treatments.

  Recruiting Phase 1 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT07001592

• Clinical and biological database for people with advanced ovarian, peritoneal, or fallopian tube cancer

  This project will collect clinical information, blood and tumor samples, and regular quality-of-life questionnaires from people newly diagnosed with advanced ovarian, peritoneal, or fallopian tube cancer to see if combining patient and tumor features can predict overall survival.

  Recruiting Centre Oscar Lambret · Lille · NCT06969833

• Fluzoparib with or without Bevacizumab for treating advanced ovarian cancer

  This study is testing whether a new drug called Fluzoparib, alone or with another drug called Bevacizumab, can help people with advanced ovarian cancer caused by BRCA1/2 mutations do better than standard chemotherapy.

  Recruiting Phase 2 Qilu Hospital of Shandong University · Jinan, Shandong · NCT06735326

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.